Sensient Technologies Valuation
Is SXT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SXT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SXT ($77.99) is trading above our estimate of fair value ($64.66)
Significantly Below Fair Value: SXT is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SXT?
Key metric: As SXT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SXT's PE Ratio? | |
|---|---|
| PE Ratio | 37.2x |
| Earnings | US$88.73m |
| Market Cap | US$3.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 16x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does SXT's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 21.6x | ||
KWR Quaker Chemical | 23.7x | 18.3% | US$2.9b |
IOSP Innospec | 20.4x | 6.9% | US$3.0b |
ASH Ashland | 18.9x | 5.0% | US$3.7b |
FUL H.B. Fuller | 23.3x | 14.1% | US$4.2b |
SXT Sensient Technologies | 37.2x | 20.2% | US$3.4b |
Price-To-Earnings vs Peers: SXT is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the peer average (21.2x).
Price to Earnings Ratio vs Industry
How does SXT's PE Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Earnings vs Industry: SXT is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the US Chemicals industry average (23.3x).
Price to Earnings Ratio vs Fair Ratio
What is SXT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 37.2x |
| Fair PE Ratio | 19.3x |
Price-To-Earnings vs Fair Ratio: SXT is expensive based on its Price-To-Earnings Ratio (37.2x) compared to the estimated Fair Price-To-Earnings Ratio (19.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$77.99 | US$86.50 +10.9% | 1.7% | US$88.00 | US$85.00 | n/a | 2 |
| Nov ’25 | US$75.64 | US$86.50 +14.4% | 1.7% | US$88.00 | US$85.00 | n/a | 2 |
| Oct ’25 | US$78.47 | US$86.50 +10.2% | 1.7% | US$88.00 | US$85.00 | n/a | 2 |
| Jul ’25 | US$73.66 | US$79.00 +7.2% | 1.3% | US$80.00 | US$78.00 | n/a | 2 |
| Jun ’25 | US$77.67 | US$79.00 +1.7% | 1.3% | US$80.00 | US$78.00 | n/a | 2 |
| May ’25 | US$73.65 | US$79.00 +7.3% | 1.3% | US$80.00 | US$78.00 | n/a | 2 |
| Apr ’25 | US$68.69 | US$69.50 +1.2% | 0.7% | US$70.00 | US$69.00 | n/a | 2 |
| Mar ’25 | US$66.68 | US$69.50 +4.2% | 0.7% | US$70.00 | US$69.00 | n/a | 2 |
| Feb ’25 | US$62.85 | US$72.00 +14.6% | 2.8% | US$74.00 | US$70.00 | n/a | 2 |
| Jan ’25 | US$66.00 | US$72.00 +9.1% | 2.8% | US$74.00 | US$70.00 | n/a | 2 |
| Dec ’24 | US$59.72 | US$72.00 +20.6% | 2.8% | US$74.00 | US$70.00 | n/a | 2 |
| Nov ’24 | US$56.03 | US$75.50 +34.7% | 7.3% | US$81.00 | US$70.00 | US$75.64 | 2 |
| Oct ’24 | US$58.48 | US$77.00 +31.7% | 9.1% | US$84.00 | US$70.00 | US$78.47 | 2 |
| Sep ’24 | US$62.01 | US$77.00 +24.2% | 9.1% | US$84.00 | US$70.00 | US$77.84 | 2 |
| Aug ’24 | US$63.69 | US$77.00 +20.9% | 9.1% | US$84.00 | US$70.00 | US$76.01 | 2 |
| Jul ’24 | US$71.13 | US$85.00 +19.5% | 10.0% | US$92.00 | US$73.00 | US$73.66 | 3 |
| Jun ’24 | US$73.01 | US$85.00 +16.4% | 10.0% | US$92.00 | US$73.00 | US$77.67 | 3 |
| May ’24 | US$75.79 | US$85.00 +12.2% | 10.0% | US$92.00 | US$73.00 | US$73.65 | 3 |
| Apr ’24 | US$76.56 | US$84.00 +9.7% | 11.8% | US$92.00 | US$70.00 | US$68.69 | 3 |
| Mar ’24 | US$74.99 | US$84.00 +12.0% | 11.8% | US$92.00 | US$70.00 | US$66.68 | 3 |
| Feb ’24 | US$76.99 | US$84.00 +9.1% | 11.8% | US$92.00 | US$70.00 | US$62.85 | 3 |
| Jan ’24 | US$72.92 | US$85.33 +17.0% | 12.7% | US$94.00 | US$70.00 | US$66.00 | 3 |
| Dec ’23 | US$74.49 | US$85.33 +14.6% | 12.7% | US$94.00 | US$70.00 | US$59.72 | 3 |
| Nov ’23 | US$70.43 | US$85.33 +21.2% | 12.7% | US$94.00 | US$70.00 | US$56.03 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Chemtrade Logistics Income Fund
CA$1.4b
Offers industrial chemicals and services in Canada, the United States, and South America.
CGIF.F
CA$8.31
7D
0.2%
1Y
28.8%
Mativ Holdings
US$716.7m
Manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally.
MATV
US$14.02
7D
12.8%
1Y
14.2%
Eldorado Gold
CA$4.7b
Engages in the mining, exploration, development, and sale of mineral products primarily in Turkey, Canada, Greece, and Romania.
EGO
CA$15.69
7D
-1.9%
1Y
28.0%